Switzerland· 67129001
Procysbi 25 mg, gélules gastro-résistantes
A mercaptamine product containing mercaptaminum, registered in Switzerland by Chiesi SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Mercaptamine is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AA04 (mercaptamine), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Mercaptamine · ATC A16AA04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of mercaptamine costs, country by country.
Normalised to the WHO defined daily dose (2 g), so markets compare like for like.
- Switzerland: $589.95 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Mercaptamine · price per daily dose (2 g)
USD · FX 28 Sept 2026
- CH Switzerland$589.95
The record
At a glance
Swissmedic (Switzerland)- Active substance
- mercaptaminum
- Manufacturer
- Chiesi SA
- Country
- Switzerland (CH)
- ATC code
- A16AA04
- ATC class
- Mercaptamine
- Defined daily dose
- 2 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680671290011Fl 60 StkCHF 374.5
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mercaptamine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPROCYSBIChiesi Farmaceutici S.p.A., Parma
- NetherlandsProcysbi 25 mg maagsapresistente capsuleChiesi Farmaceutici S.p.A.
- United StatesCYSTADROPSRECORDATI RARE DISEASES, INC.
- United KingdomCystadrops 3.8mg/ml eye dropsRecordati Rare Diseases UK Ltd
- IrelandCystadrops 3.8 mg/mL eye drops solutionRecordati Rare Diseases
- PolandCystadropsRecordati Rare Diseases
- SwedenCystadrops 3,8 mg/ml Ögondroppar, lösningRecordati Rare Diseases
- BelgiumCystadrops 3.8 mg/mlRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cystadrops, Cystagon
- Liechtenstein · Cystadrops, Cystagon
- Norway · Cystadrops, Cystagon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c776f4d2-14c4-4d7a-b645-94045211cd71 GET /v1/drugs/c776f4d2-14c4-4d7a-b645-94045211cd71?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "mercaptaminum 25 mg",
"valid_from": "2024-07-01",
"limitations": "[{\"description\":\"Die Anwendung von PROCYSBI hat gemäss den Angaben der von Swissmedic genehmigten Fachinformation zu erfolgen:<br>\\nDie Einleitung der PROCYSBI-Therapie sollte unter der Kontrolle eines Arztes erfolgen, der über Erfahrung in der Behandlung von Cystinose verfügt.<br>\\nDie Mercaptamin-Therapie muss umgehend nach Bestätigung der Diagnose einer nephropathischen Cystinose (d.h. anhand eines erhöhten leukozytären Cystingehaltes) eingeleitet werden, damit ein höchstmöglicher therapeutischer Nutzen erreicht wird.<br>\\nNach Kostengutsprache durch den Krankenversicherer bzw. durch die IV-Stelle nach vorgängiger Konsultation des RAD.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-07-01\",\"validTo\":\"2027-06-30\"}]",
"galenic_form": "Kaps 25 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2024-07-01",
"self_retention_pct": 10
}See everything about mercaptamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.